LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) — Enochian BioSciences (the Company) recently announced significant advances in redirecting its focus on curing some of the world’s deadliest diseases. Last week, the company announced its oncology platform has been awarded a US patent and is in production promising first results in studies conducted in collaboration with Dr. Ana Jewett at UCLA. The company also anticipates potentially positive results from studies of its HIV platform conducted by researchers at the Fred Hutchinson Cancer Center.

“We continue to prioritize the efficient research, development and commercialization of our promising oncology and HIV pipelines,” said Dr. Mark Dybul, CEO of Enochian. “The future of Enochian is bright and we look forward to advancing potentially curative therapies for some of the world’s deadliest diseases.”

The Company also announced that it has filed a lawsuit against Serhat Gumrukcu, William Anderson Wittekind, SG & AW Holdings LLC and Seraph Research Institute in the California Superior Court for Los Angeles County. As alleged in the lawsuit, the defendants engaged in an “agreed, deliberate plan to alter, falsify and misrepresent [the Company] the results of several studies supporting his [Hepatitis B] and SARS-CoV-2/influenza pipelines.” “Defendants manipulated negative results to reflect positive results from various studies and even fabricated studies from scratch. The conduct of the defendants amounts to outrageous fraud that has caused Enochian significant damage.” Through this lawsuit, the company intends to “hold [the] The defendants are responsible for their conduct and compensate for damages resulting from their actions.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. These statements are only predictions based on current information and expectations and a number of…